title: Autotransplantation following busulfan, etoposide and cyclophosphamide in patients with non-Hodgkin's lymphoma.
abstract: The purpose of the study was to determine the toxicities and effectiveness of a novel preparative regimen of busulfan (Bu) 14 mg/kg, etoposide 50 or 60 mg/kg, and cyclophosphamide (Cy) 120 mg/kg in non-Hodgkin's lymphoma (NHL) and to analyze results using doses based on different body weight parameters and the two different etoposide doses. Three hundred and eighty-two patients aged 16 to 72 underwent first autologous transplantation with mobilized peripheral blood progenitor cells between August 1992 and December 1998 at either of two transplant centers. Mucositis was the most common toxicity. Hepatic toxicity was the most common life-threatening toxicity; severe hepatic VOD occurred in 11 patients (2.9%). Ten patients (2.6%) died from treatment-related toxicity. The 3-year progression-free survival (PFS) for the entire group was 46.9% (95% CI, 40.5-53.3%). Elevated LDH, resistance to chemotherapy, and intermediate/aggressive histology were significant adverse prognostic factors. For patients in sensitive first relapse PFS was 47.0% (95% CI, 37-57%). Neither etoposide dose nor body weight parameter utilized significantly affected outcome. In conclusion, the novel preparative regimen of Bu, etoposide and Cy results in a low incidence of treatment-related mortality and is effective in the treatment of patients with NHL. Bone Marrow Transplantation (2000) 25, 1243-1248.
authors.affiliation: Bone Marrow Transplantation Program, The Ohio State University, Arthur G James Cancer Hospital & Richard J Solove Research Institute, Columbus, Ohio 432110, USA.
authors.forename: E A
authors.initials: EA
authors.lastname: Copelan
authors.forename: S L
authors.initials: SL
authors.lastname: Penza
authors.forename: B
authors.initials: B
authors.lastname: Pohlman
authors.forename: B R
authors.initials: BR
authors.lastname: Avalos
authors.forename: M
authors.initials: M
authors.lastname: Goormastic
authors.forename: S W
authors.initials: SW
authors.lastname: Andresen
authors.forename: M
authors.initials: M
authors.lastname: Kalaycio
authors.forename: T P
authors.initials: TP
authors.lastname: Bechtel
authors.forename: M D
authors.initials: MD
authors.lastname: Scholl
authors.forename: P J
authors.initials: PJ
authors.lastname: Elder
authors.forename: S A
authors.initials: SA
authors.lastname: Ezzone
authors.forename: L C
authors.initials: LC
authors.lastname: O'Donnell
authors.forename: M B
authors.initials: MB
authors.lastname: Tighe
authors.forename: G L
authors.initials: GL
authors.lastname: Risley
authors.forename: D C
authors.initials: DC
authors.lastname: Young
authors.forename: B J
authors.initials: BJ
authors.lastname: Bolwell
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects; D002066:Busulfan / Q000008:administration & dosage / Q000009:adverse effects; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000473:pathology / Q000628:therapy*; D016019:Survival Analysis; D014182:Transplantation, Autologous
chemical_list: D005047:Etoposide; D003520:Cyclophosphamide; D002066:Busulfan